News | June 13, 2014

Cardinal Health Ships 2 Millionth Mynx Vascular Closure Device

Company celebrates milestone after recent acquisition of AccessClosure

Mynx Vascular Closure Device Cardinal Health 2 Millionth Shipment June 2014

June 13, 2014 — Cardinal Health announced the 2 millionth shipment of the Mynx Vascular Closure Device (VCD). The Mynx product family of vascular closure devices combines the reliability of an easy-to-use deployment system with the security of mechanical closure and the safety of an extravascular sealant that enables physicians to seal an arteriotomy securely without leaving anything permanently behind in the artery.

“There are several vascular closure devices on the market, but most of them leave material behind, either inside the femoral artery, like a plug, or material in the arterial wall, like a suture or clip, which limits their use in certain situations,” said Najam Wasty, director of invasive cardiovascular laboratory and director of Interventional Cardiology Fellowship Training Program at a major teaching institution. “The major advantage of the Mynx VCD is that it is extravascular. In other words, it does not leave any materials permanently inside the artery or in the wall of the artery. Many physicians find this feature attractive since it allows safe use of the Mynx VCD in most situations.”

The first Mynx Vascular Closure Device received U.S. Food and Drug Administration (FDA) approval in May 2007. The Mynx product family includes the new Mynx Ace Vascular Closure Device, launched in 2013 in the United States, and the MynxGrip Vascular Closure Device, launched in 2012. Mynx devices use proprietary Grip Technology, which employs an extravascular sealant that actively adheres to the artery for safe and secure mechanical closure and dissolves within 30 days, leaving nothing permanently behind in the healed artery.  

Cardinal Health completed its acquisition of AccessClosure in May.

The Mynx product family is clinically proven and has been featured in several peer-reviewed articles.

For more information: www.accessclosure.com

Related Content

FDA Approves Vascade MVP Vascular Closure System
Technology | Vascular Closure Devices | December 20, 2018
Cardiva Medical Inc. announced the company has received premarket approval (PMA) from the U.S. Food and Drug...
PerQseal Large Bore Closure Device Launches in Europe
News | Vascular Closure Devices | November 21, 2018
Vivasure Medical Ltd. recently announced the European launch of the PerQseal closure device for large-bore...
Vascade MVP Reduces Time to Ambulation Follow EP Procedures
News | Vascular Closure Devices | November 11, 2018
The Vascade MVP vascular closure system met its endpoints compared to manual compression in a pivotal clinical study...
Technology | Vascular Closure Devices | November 05, 2018
November 2, 2018 — Cordis, a Cardinal Health company, today announced the U.S.
Teleflex Acquires Essential Medical
News | Vascular Closure Devices | October 05, 2018
Teleflex Inc. announced the acquisition of Essential Medical Inc. Based in Exton, Pa., Essential Medical is a privately...
Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial
News | Vascular Closure Devices | May 10, 2018
Cardiva Medical Inc. announced the completion of the AMBULATE pivotal trial, one of several clinical trials in the...
Cardiva Medical Announces $41 Million for AMBULATE Vascular Closure Device Trial
News | Vascular Closure Devices | February 21, 2018
Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional...
The bioresorbable Cordis Mynx Grip vascular closure device seals arteriotomies without use of permanent hardware.

The bioresorbable Cordis MynxGrip vascular closure device seals arteriotomies without use of permanent hardware.

Feature | Vascular Closure Devices | January 22, 2018 | Dave Fornell
While manual compression remains the gold standard for hemostasis of catheterization vascular access site arteriotomi
Overlay Init